Dec. 31 Company Quick Takes: A first for BeiGene; plus MorphoSys, Junshi-CSPC, Acceleron-Fulcrum and Solasia-EditForce

By BioCentury Staff | Dec 31, 2019 | 10:05 PM GMT
Editor's note: Updated on Jan 1, 2020 at 2:04 AM GMT

First-ever China approval for homegrown BeiGene drug
China’s National Medical Products Administration approved anti-PD-1 mAb tislelizumab from BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) to treat classical Hodgkin lymphoma in a third-line setting. The approval is the first in China from

Read the full 374 word article

How to gain access

Continue reading with a
two-week free trial.